Want to see BLSM full AI Analyst Report?

BlossomHill Therapeutics, Inc. (BLSM) Financial Statements

14 Followers

BlossomHill Therapeutics, Inc. Financial Overview

BlossomHill Therapeutics, Inc.'s market cap is currently $802.57M. The company's EPS TTM is $; its P/E ratio is -2.36; BlossomHill Therapeutics, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24
Income Statement
Total Revenue	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00
Operating Income	$ -64.02M	$ -36.40M
EBITDA	$ -63.58M	$ -36.05M
Net Income	$ -60.55M	$ -30.70M
Balance Sheet
Cash & Short-Term Investments	$ 136.68M	$ 100.15M
Total Assets	$ 162.97M	$ 106.78M
Total Debt	$ 22.40M	$ 525.00K
Net Debt	$ -114.28M	$ -99.62M
Total Liabilities	$ 294.70M	$ 179.66M
Stockholders' Equity	$ -131.73M	$ -72.88M
Cash Flow
Free Cash Flow	$ -47.99M	$ -31.51M
Operating Cash Flow	$ -46.92M	$ -31.42M
Investing Cash Flow	$ -1.07M	$ -92.00K
Financing Cash Flow	$ 84.53M	$ 17.56M

Currency in USD

BlossomHill Therapeutics, Inc. Earnings and Revenue History

Income Statement >

BlossomHill Therapeutics, Inc. Debt to Assets

Balance Sheet >

BlossomHill Therapeutics, Inc. Cash Flow

Cash Flow >

BlossomHill Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >